A new once-daily diabetes pill called elecoglipron reduced blood sugar levels by up to 1.88% in a 26-week study of 404 people, compared to only 0.15% with placebo. According to Gram Research analysis of this phase 2b trial published in The Lancet, the drug works similarly to existing GLP-1 injections but offers a pill option instead. However, the medication is still in early testing and won’t be available to patients for several years.
Researchers tested a new once-daily pill called elecoglipron that helps control blood sugar in people with type 2 diabetes. In a study of 404 participants across nine countries, the pill reduced blood sugar levels more effectively than a placebo, with the highest dose reducing HbA1c (a measure of long-term blood sugar control) by nearly 2%. The most common side effects were stomach-related issues like nausea and constipation, which are typical for this class of diabetes medication. According to Gram Research analysis, these results suggest elecoglipron could become a new treatment option, though more testing is needed before it becomes available to patients.
Key Statistics
A 2026 phase 2b randomized controlled trial of 404 adults found that the highest dose of elecoglipron reduced blood sugar levels by 1.88% after 26 weeks, compared to 0.15% with placebo—demonstrating approximately 12 times greater effectiveness than placebo.
In the SOLSTICE trial published in The Lancet in 2026, gastrointestinal side effects including nausea, constipation, diarrhea, and vomiting were reported in 63-87% of participants taking elecoglipron across different doses, consistent with other GLP-1 receptor agonist medications.
The 2026 SOLSTICE study of 404 participants showed that elecoglipron’s blood sugar reduction (1.88% at the highest dose) was comparable to the existing GLP-1 injection semaglutide (approximately 1.5% reduction), suggesting similar effectiveness with the advantage of once-daily oral administration.
Among 404 participants in the 2026 elecoglipron trial, the drug reduced blood sugar levels in a dose-dependent manner, with the 5 mg dose reducing HbA1c by 0.91%, the 15 mg dose by approximately 1.3%, and the 75 mg dose by 1.88%.
The Quick Take
- What they studied: How well a new diabetes pill called elecoglipron works at controlling blood sugar compared to a fake pill (placebo) and an existing diabetes injection
- Who participated: 404 adults with type 2 diabetes from nine countries (Canada, Germany, Hungary, Japan, Poland, Slovakia, Spain, UK, and USA). Average age was 58 years, and most were overweight or obese
- Key finding: The highest dose of elecoglipron reduced blood sugar levels by 1.88% after 26 weeks, compared to only 0.15% with placebo—meaning the new pill worked about 12 times better than placebo
- What it means for you: If approved, elecoglipron could offer people with type 2 diabetes a new once-daily pill option instead of injections. However, it’s still in early testing stages and won’t be available for several years. Talk to your doctor about current treatment options
The Research Details
This was a phase 2b randomized controlled trial, which is an early-stage test of a new drug. Researchers randomly assigned 404 people with type 2 diabetes to receive different doses of elecoglipron, a placebo (fake pill), or an existing diabetes injection called semaglutide. The study lasted 26 weeks (about 6 months). Participants took their assigned treatment once daily by mouth, with no restrictions on food or drinks. Neither the participants nor their doctors knew which people were getting the real drug versus the placebo, which helps prevent bias in the results.
The study took place at medical centers and hospitals across nine countries. Researchers chose sites that had the proper equipment, trained staff, and access to patients with type 2 diabetes. The study tested different doses of elecoglipron (5 mg, 15 mg, 25 mg, 50 mg, and 75 mg) and different ways of increasing the dose over time to find the best balance between effectiveness and side effects.
Testing a new drug in a randomized, double-blind format (where neither patients nor doctors know who gets the real drug) is the gold standard for proving a medication works. This design prevents people’s expectations from influencing the results. By testing multiple doses and dose-escalation schedules, researchers can identify which approach works best with the fewest side effects. Testing across nine countries helps ensure the results apply to diverse populations
This study was published in The Lancet, one of the world’s most respected medical journals, which means it underwent rigorous peer review. The study was well-designed with proper randomization and blinding. However, this is a phase 2b trial, which is early-stage testing. The sample size of 404 is moderate for this type of study. The study lasted only 26 weeks, so we don’t know about long-term effects. More testing (phase 3 trials) with larger groups and longer follow-up is needed before the drug can be approved for patient use
What the Results Show
The main finding was that elecoglipron reduced blood sugar levels (measured by HbA1c) in a dose-dependent manner, meaning higher doses worked better. The 5 mg dose reduced HbA1c by 0.91%, the 15 mg dose by approximately 1.3%, and the highest dose (75 mg with faster dose increases) reduced it by 1.88%. In comparison, the placebo group only improved by 0.15%, and the existing semaglutide injection reduced HbA1c by approximately 1.5%.
These reductions are clinically meaningful. For context, a reduction of 1-2% in HbA1c typically translates to better long-term blood sugar control and reduced risk of diabetes complications like kidney disease, vision problems, and nerve damage.
The dose-response relationship was clear: as the dose increased, blood sugar control improved. This suggests that doctors could potentially adjust doses based on individual patient needs, similar to how other diabetes medications are used.
The study also measured body weight changes. Participants taking elecoglipron experienced modest weight loss, which is beneficial since excess weight makes diabetes harder to control. The study confirmed that elecoglipron worked across different populations and in people taking different baseline medications (diet and exercise alone, metformin, or SGLT2 inhibitors). This suggests the drug could be used as an add-on therapy for people whose current treatments aren’t working well enough
Elecoglipron belongs to the same drug class as semaglutide (Ozempic, Wegovy) and tirzepatide (Zepbound, Mounjaro), which are GLP-1 receptor agonists. The key difference is that elecoglipron is a small molecule taken as a pill once daily, while semaglutide and tirzepatide are injections. The blood sugar reduction seen with elecoglipron (1.88% at the highest dose) is comparable to what’s seen with these existing drugs at similar early testing stages. This suggests elecoglipron could be an effective alternative for people who prefer pills to injections
This study has several important limitations. First, it’s a phase 2b trial with only 404 participants—larger phase 3 trials with thousands of people are needed to confirm these results. Second, the study lasted only 26 weeks, so we don’t know if the benefits continue or if side effects change over longer periods. Third, most participants were White (69%), so results may not apply equally to other racial and ethnic groups. Fourth, the study didn’t measure important long-term outcomes like heart attacks, strokes, or kidney disease prevention. Finally, this is early-stage testing, and the drug is not yet approved for patient use
The Bottom Line
If you have type 2 diabetes, continue taking your current medications as prescribed by your doctor. Elecoglipron is not yet available and won’t be for several years at minimum. Stay informed about new treatment options by discussing them with your healthcare provider. Current proven treatments like metformin, GLP-1 injections, and SGLT2 inhibitors remain your best options now. Confidence level: High for continuing current treatments; Low for elecoglipron (still in testing)
People with type 2 diabetes who struggle with injections or prefer taking pills should follow this research. Those who haven’t achieved good blood sugar control with current medications may benefit from new options. Healthcare providers and diabetes specialists should monitor this drug’s development. People who are overweight or obese with type 2 diabetes may be particularly interested, since this drug showed modest weight loss benefits. This research is less relevant for people with type 1 diabetes or those with well-controlled type 2 diabetes on current treatments
If elecoglipron continues development successfully, it will need to complete phase 3 trials (typically 1-2 years), then be reviewed by regulatory agencies like the FDA (typically 1-2 years). Realistically, the drug would not be available to patients for at least 3-5 years, possibly longer. Even after approval, insurance coverage and availability may vary
Frequently Asked Questions
Is elecoglipron available to buy right now for type 2 diabetes?
No, elecoglipron is not yet available. It’s still in phase 2b testing, the early stage of drug development. The drug must complete phase 3 trials and receive regulatory approval before patients can use it, which typically takes 3-5 years or longer.
How does elecoglipron compare to semaglutide or Ozempic for diabetes?
Elecoglipron and semaglutide both belong to the GLP-1 drug class and show similar blood sugar reduction (around 1.5-1.88%). The main difference is that elecoglipron is a once-daily pill, while semaglutide is a weekly injection. Both are effective, but elecoglipron offers a pill option for people who prefer not to inject.
What are the side effects of elecoglipron based on this study?
The most common side effects were gastrointestinal issues: nausea, constipation, diarrhea, and vomiting. These occurred in 63-87% of participants depending on the dose. These side effects are typical for GLP-1 medications and often improve over time as the body adjusts.
Can elecoglipron help with weight loss like other GLP-1 drugs?
The study showed modest weight loss with elecoglipron, similar to other GLP-1 medications. However, weight loss wasn’t the primary focus of this early-stage trial. More research is needed to determine how much weight loss patients might expect.
Who would be a good candidate for elecoglipron if it becomes available?
People with type 2 diabetes who prefer pills over injections, those whose blood sugar isn’t well-controlled on current medications, and those who are overweight or obese might benefit. Your doctor would determine if it’s appropriate based on your individual health situation and current treatments.
Want to Apply This Research?
- Track your current HbA1c levels every 3 months and record your blood sugar readings daily. Note which medications you’re taking and any side effects. This baseline data will help you and your doctor evaluate whether new treatments like elecoglipron might benefit you when they become available
- Use the app to set reminders for taking your current diabetes medications consistently. Log your meals and physical activity to optimize your current treatment. Monitor your weight weekly. These actions will help you achieve the best possible blood sugar control with available treatments while you wait for new options
- Create a long-term tracking dashboard showing HbA1c trends, weight changes, and medication adherence. Set quarterly check-in reminders to review your progress with your doctor. When new treatments become available, you’ll have clear baseline data to compare against. Share this data with your healthcare provider to make informed decisions about treatment changes
This article summarizes research from a phase 2b clinical trial and is for educational purposes only. Elecoglipron is not yet approved for patient use and is still undergoing testing. Do not make any changes to your diabetes treatment based on this information. Always consult with your healthcare provider or endocrinologist before starting, stopping, or changing any diabetes medication. The findings presented here are preliminary and may change as additional research is conducted. If you have type 2 diabetes, continue taking your current medications as prescribed and maintain regular check-ups with your doctor.
This research translation is published by Gram Research, the science division of Gram, an AI-powered nutrition tracking app.